Clinical trial finds varenicline improves abstinence in youths compared to placebo, suggesting potential effectiveness.
More youths in the varenicline group than placebo group adhered to their medication and undertook counseling, and this may have biased the data toward higher abstinence in the varenicline group. The results of ViVA do not apply to adults, and those youths who are not actively seeking to stop vaping, and youths who smoke and are, probably, addicted to smoking/nicotine. Longer-term clinical trials in both youths and adults will be necessary to determine whether varenicline causes meaningful abstinence and is safe in long-term vaping.
No takes yet. Share an insight, caveat, or question.
Sheila A Doggrell (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Expert Opinion on Pharmacotherapy